SURVYR

AMRX

Amneal Pharmaceuticals, Inc.
$20.15
+$0.31 (1.54%)Oct 21 close
Health CareS&P 600 CompareTechnicals
1M3M6M1Y2Y
-5%+23%+51%+79%+107%Oct 2025Oct 2026Apr 202652w high $21.1852w low $9.99
AMRXSPY
Wall St. Highest PT $27.00 (+34.0%) Wall St. Avg PT $22.71 (+12.8%)
$10$14$19$23$28POC $13Hi $27Avg $23
Underwater Drawdown %Max DD -22.3%Current -1.7%
0.0%-22.3%
Relative Strength vs SPY+80.3% vs SPYOutperforming
+98%0%-98%
1W
+$1.25 (6.59%)
1M
−$0.01 (0.07%)
3M
+$2.40 (13.49%)
6M
+$7.33 (57.14%)
YTD
+$7.55 (59.88%)
1Y
+$9.86 (95.77%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Analyst price targets
Current price$20.15
Average target$22.71
+$2.57 (+12.8%) upsideaverage target vs current price
CurrentAverageMedian
Low$20.00
Median$22.71
High$27.00
12-month Wall Street target range
Recent analyst rating changes · 8
Initiated
2026-09-23 · Oppenheimer started covering AMRX at Outperform
Reiterated
2026-09-17 · Barclays reiterated Overweight on AMRX
Initiated
2026-09-09 · Leerink Partners started covering AMRX at Outperform
Reiterated
2026-08-03 · UBS reiterated Buy on AMRX
Reiterated
2026-07-15 · UBS reiterated Buy on AMRX
Reiterated
2026-05-20 · Barclays reiterated Overweight on AMRX
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$7.0B
P/E (last 12 months)41.1
P/E (next 12 months, estimated)16.9
52-week range$9.99 – $21.18
Revenue growth (latest quarter vs a year ago)+9.9%
Dividend yieldNo dividend
Average analyst price target$22.71 (+13%)

What they do

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems.

Healthcare · Drug Manufacturers - Specialty & Generic
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
92nd percentile in sector
A
12-1 return: +86.1%
Percentile within its GICS sector across the S&P 1500.
Growth
58th percentile in sector
B-
Revenue growth (YoY): +9.9%
Percentile within its GICS sector across the S&P 1500.
Value
64th percentile in sector
B-
Forward E/P: 6.2% · EBITDA/EV: 7.8%
Percentile within its GICS sector across the S&P 1500.
Profitability
71st percentile in sector
B
Profit margin: +5.0% · Return on equity: +613.0%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
ranked 25 of 589 · 12-month momentum 77.0%
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

AMRX earningsNext report in 6 days
Next report · quarter Sep 2026
Tue Nov 3, 2026Before the open
EPS consensus$0.23 range $0.20–$0.28
Revenue consensus$812.1M 6 analysts
Last 4 quarters · EPS vs estimate
Jul 30, 2026$0.30est $0.23+30.3%Above estimates
May 7, 2026$0.27est $0.17+59.6%Above estimates
Feb 27, 2026$0.21est $0.18+14.1%Above estimates
Oct 30, 2025$0.17est $0.14+22.9%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-21 11:28:19 ET
24-1125-0225-0525-0825-1026-0226-0526-070.000.30
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$796.2M+9.9%
2026-03-31$722.5M–
2025-12-31$814.3M–
2025-09-30$784.5M–
2025-06-30$724.5M–

News & catalysts

More news
Amneal Pharmaceuticals (AMRX) files 8-K
SEC 8-K · Oct 23
Rating changes
Initiated
2026-09-23 · Oppenheimer started covering AMRX at Outperform
Reiterated
2026-09-17 · Barclays reiterated Overweight on AMRX
Initiated
2026-09-09 · Leerink Partners started covering AMRX at Outperform
Reiterated
2026-08-03 · UBS reiterated Buy on AMRX
Reiterated
2026-07-15 · UBS reiterated Buy on AMRX
Reiterated
2026-05-20 · Barclays reiterated Overweight on AMRX

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-21 11:28:19 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026